Atossa Therapeutics has reported positive interim safety data from its Phase I clinical trial of nasal spray and COVID-19 drug candidate, AT-301. The drug is designed for at-home use to help curb COVID-19 symptoms and slow the infection rate – it is not intended for patients who require hospitalization. Yourway has an advanced direct-to-patient offering, where we deliver trial materials directly to and from patients. This personalized care approach has proven effective in increasing patient satisfaction and improving recruitment and retention rates, leading to cost savings, shorter development timelines and improved health outcomes.